Sartorius AG (GB:0NIQ)
LSE:0NIQ
0NIQ Stock Chart & Stats
€196.40
€3.40(1.81%)
At close: 4:00 PM EST
€196.40
€3.40(1.81%)
Day’s Range― - ―
52-Week Range€143.40 - €208.00
Previous CloseN/A
Volume8.00
Average Volume (3M)266.00
Market Cap
€13.63B
Enterprise Value€19.12B
Total Cash (Recent Filing)€541.40M
Total Debt (Recent Filing)€4.45B
Price to Earnings (P/E)110.2
Beta1.69
Next Earnings
Apr 23, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)1.26
Shares Outstanding37,440,000
10 Day Avg. Volume141
30 Day Avg. Volume266
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€246.00Price Target Upside25.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.55
Revenue Forecast (FY)€3.76B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueSustained mid‑teens consumables growth indicates a durable installed‑base model with high repeat purchase frequency. That recurring revenue smooths sales volatility, supports higher gross margins than one‑off equipment, and underpins long‑term cash generation as customers run ongoing R&D and manufacturing.
Bioprocess Solutions (BPS) StrengthBPS is the company’s higher‑margin core, showing above‑market sales and notable margin expansion. Structural demand from biopharma development and manufacturing, plus mid‑teens consumable growth within BPS, provides a durable profit engine that drives group EBITDA and supports capacity investments.
Strategic Innovation And Capacity ExpansionOngoing product launches, targeted M&A (MATTEK) and multi‑site capacity builds deepen end‑to‑end capabilities and address future demand. These strategic moves strengthen competitive moat, broaden addressable markets (e.g., 3D cell models) and increase installed base for recurring consumables over the medium term.
Bears Say
Elevated LeverageLeverage remains elevated for a med‑tech tools and consumables group, limiting financial flexibility. High gross/net debt raises refinancing and interest costs risk, constrains ability to fund organic growth or M&A without using cash flow, and prolongs vulnerability if margins or cash conversion weaken.
Weakened Cash GenerationMaterial decline in operating cash flow and FCF reduces capacity to deleverage and self‑fund elevated CapEx (~12% of sales). Weaker cash conversion increases reliance on external financing or slower paydown, potentially delaying return of leverage to target levels and constraining shareholder‑facing actions.
Equipment Softness And LPS Margin PressureSoft equipment demand and deliberate investments in Advanced Cell Models depress LPS margins and flatten sales growth. Structural mix shifts toward lower‑margin or investment‑heavy products can weigh on overall group margin sustainability and require multi‑period returns to justify margin dilution.
Sartorius News
0NIQ FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest share price was €143.40 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €13.63B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Apr 23, 2026 which is in 14 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Feb 03, 2026. The company reported €1.26 earnings per share for the quarter, missing the consensus estimate of €1.312 by -€0.052.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.39%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.29.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.26 in its last earnings report, missing expectations of €1.312. Following the earnings report the stock price went up 4.157%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in GB:0NIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€246.00 (25.25% Upside)
€246.00 (25.25% Upside)
Insider Transactions
Bought Shares
Worth €286.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
5.77%
Trailing 12-Months
Asset Growth
-3.82%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
0NIQ Stock 12 Month Forecast
Average Price Target
€246.00
▲(25.25% Upside)
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―
Options Prices
Currently, No data available
---